12 NASDAQ Stocks with Biggest Upside Potential According to Analysts

8. Geron Corp. (NASDAQ:GERN)

Average Upside Potential as of November 21: 85.87%

Geron Corp. (NASDAQ:GERN) is a biotechnology company specializing in developing and commercializing therapeutic products for cancer that inhibit telomerase, an enzyme linked to cell division and cancer proliferation. Its primary product, Imetelstat, is a first-in-class telomerase inhibitor to treat various blood cancers, including myelodysplastic syndromes and myelofibrosis.

The brand name for Imetelstat at the company is RYTELO. In the first full quarter of RYTELO’s launch in the US, which is Q3 2024, the company had $28.27 million in net product revenue, surpassing expectations by $9.26 million. This strong performance reflects both the significant unmet need in lower-risk MDS and RYTELO’s differentiated clinical profile, causing revenue to grow by 17,138.41% year-over-year.

RYTELO became available to prescribers on June 27 and the demand has steadily increased month-over-month, with 388 ordering centers representing ~45% of key targeted accounts. Its efficacy in improving red blood cell transfusion independence and hemoglobin levels is well-recognized by treating physicians. It’s also important to note that ~70% of US-covered lives have implemented medical coverage policies consistent with RYTELO’s FDA label.

Management anticipates potential EU approval for RYTELO in H1 2025, following a CHMP review expected to conclude in late 2024 or early 2025. It’s actively preparing for a potential launch in select EU markets starting in 2026. These efforts, combined with the company’s current financial performance position Geron Corp. (NASDAQ:GERN) to become an industry leader.